Azitra, Inc. (AZTR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Azitra reported revenue of $0, down 100.0% from $7,500 the year before. Net income was -$11.0M, or -$2.25 per diluted share. Operating activities generated -$11.2M of cash, leaving -$11.2M of free cash flow. At fiscal year end, Azitra held $5.0M in total assets against $1.2M in total liabilities, including $2.1M of cash and equivalents.
Open the full interactive Azitra financials → Quarterly statements, key ratios, valuation history and price charts.
Azitra Key Stats
| Share Price | $0.07 |
|---|---|
| Market Cap | $1.4M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.07 – $0.75 |
| Shares Outstanding | 19.3 million (basic, 2026 Q2) |
Azitra Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $686,000 | $7,500 | $0 |
| Operating Income | -$7.6M | -$11.0M | -$11.0M |
| Pre-Tax Income | -$11.3M | -$9.0M | -$10.9M |
| Income Tax | $17,308 | $9,031 | $8,319 |
| Net Income | -$11.3M | -$9.0M | -$11.0M |
| Diluted EPS | -$366.00 | -$15.80 | -$2.25 |
Azitra Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.8M | -$2.2M | -$3.9M | -$3.3M |
| Diluted EPS | -$0.67 | -$0.46 | -$0.25 | -$0.17 |
Azitra Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $1.8M | $4.6M | $2.1M |
| Current Assets | $2.5M | $5.2M | $3.0M |
| Total Assets | $5.1M | $7.4M | $5.0M |
| Current Liabilities | $1.6M | $1.4M | $1.1M |
| Total Liabilities | $2.2M | $1.7M | $1.2M |
| Shareholders' Equity | $2.9M | $5.7M | $3.8M |
Azitra Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$7.4M | -$10.2M | -$11.2M |
| Cash From Investing | -$318,259 | -$379,246 | -$182,909 |
| Cash From Financing | $6.0M | $13.3M | $8.9M |
| Free Cash Flow | -$7.4M | -$10.2M | -$11.2M |
Figures from Azitra's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Azitra financials page for every line item.
Azitra Company Profile
| Ticker | AZTR |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Branford, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001701478 |
Frequently Asked Questions
What was Azitra's revenue in fiscal 2025?
Azitra (AZTR) reported revenue of $0 for fiscal 2025.
What is Azitra's annual revenue history?
Azitra's annual revenue by fiscal year: 2023: $686,000; 2024: $7,500; 2025: $0.
What was Azitra's net income in fiscal 2025?
Azitra reported net income of -$11.0M for fiscal 2025.
What was Azitra's earnings per share (EPS) in fiscal 2025?
Azitra's diluted EPS was -$2.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Azitra generate in fiscal 2025?
Azitra generated -$11.2M of free cash flow in fiscal 2025.
What was Azitra's revenue last quarter?
In its most recent reported quarter (2026 Q2), Azitra reported revenue of $0.
How many shares of Azitra are outstanding?
Azitra reported a weighted average of 19.3 million basic shares outstanding in 2026 Q2.
What is Azitra's market cap?
Based on its latest closing price, Azitra (AZTR) has a market capitalization of about $1.4M.
When does Azitra's fiscal year end?
Azitra's fiscal year end, as registered with the SEC, is December 31.
Where is Azitra headquartered?
Azitra lists its business address in Branford, Connecticut in its SEC filings.